Why the study?
Does nabumetone cause less interference with human platelet reactivity ex vivo compared to naproxen?
Does nabumetone cause less interference with human platelet reactivity ex vivo compared to naproxen?
Nabumetone may cause less interference with haemostasis than other non-steroidal anti-inflammatory drugs like naproxen.
Nabumetone may spare platelet aggregation more than naproxen ex vivo; hypothesis-generating for differential bleeding risk, needs clinical confirmation.
The effect of nabumetone (BRL 14777) on human platelet reactivity ex vivo was compared with that of naproxen at equitherapeutic doses in the same six subjects. Nabumetone had only a weak and equivocal effect on collagen-induced and second phase aggregation in response to adenosine diphosphate and adrenaline. After nabumetone, platelets fully aggregated in response to sodium arachidonate, though approximately twice as much was needed as on control occasions. Sodium arachidonate was unable to elicit a full aggregation response after naproxen. These results suggest that nabumetone may cause less interference with haemostasis than other non-steroidal anti-inflammatory drugs.
No takes yet. Share an insight, caveat, or question.
Nunn et al. (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: